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Abstract
Background: The receptor tyrosine kinase Met is involved in the progression and metastasis of numerous human cancers.
Although overexpression and autocrine activation of the Met signaling pathway are commonly found in human cancers,
mutational activation of Met has been observed in small cell and non-small cell lung cancers, lung adenocarcinomas, renal
carcinomas, and mesotheliomas.
Methodology/Principal Findings: To investigate the influence of mutationally activated Met in tumorigenesis, we utilized a
novel mouse model. Previously, we observed that various Met mutations developed unique mutation-specific tumor spectra
on a C57BL/6 background. Here, we assessed the effect of genetic background on the tumorigenic potential of mutationally
activated Met. For this purpose, we created congenic knock-in lines of the Met mutations D1226N, M1248T, and Y1228C on
the FVB/N background. Consistent with the mutation-specific tumor spectra, several of the mutations were associated with
the same tumor types as observed on C57BL/6 background. However, on the FVB/N background most developed a high
incidence of mammary carcinomas with diverse histopathologies.
Conclusions/Significance: This study demonstrates that on two distinct mouse backgrounds, Met is able to initiate
tumorigenesis in multiple cell types, including epithelial, hematopoietic, and endothelial. Furthermore, these observations
emphasize that even a modest increase in Met activation can initiate tumorigenesis with both the Met mutational spectra
and host background having profound influence on the type of tumor generated. Greater insight into the interaction of
genetic modifiers and Met signaling will significantly enhance our ability to tailor combination therapies for Met-driven
cancers.
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Introduction
Aberrant activity of tyrosine kinases through overexpression
and/or mutation has been associated with numerous human
cancers. The receptor tyrosine kinase ErbB2 (Her2/Neu) is
overexpressed in 20% of breast cancers [1]; epidermal growth
factor receptor (EGFR) is highly expressed in non-small-cell lung
cancers [2]; and the FLT3 receptor is mutated in 30% of acute
myelogenous leukemias (AML) and other hematological malig-
nancies [3]. These studies and numerous others have demonstrat-
ed the significant impact of altered tyrosine kinase signaling in
tumor initiation and progression in various tissue types. Those
cancers that are addicted to the activation of a specific tyrosine
kinase are optimal targets for therapy. Consequently, tyrosine
kinases have been a substantial focus for the development of
targeted therapeutics.
The receptor tyrosine kinase Met is an oncogene involved in the
progression and metastasis of numerous human cancers [4]. The
Met receptor is a disulfide-linked heterodimer containing an
extracellular region (including a sema domain, a cysteine-rich
domain, and four IgG domains), a transmembrane region, and an
intracellular region (including the juxtamembrane domain, the
kinase domain, and the C-terminal docking site). In normal
physiological conditions, Met is expressed primarily by epithelial
cells at the cell surface and is activated through paracrine binding
of the ligand hepatocyte growth factor/scatter factor (HGF/SF)
[5,6,7]. In neoplastic conditions, increased Met activity occurs
through numerous mechanisms including overexpression of Met
and/or HGF/SF, autocrine signaling, or mutational activation. In
transformed cells, Met activation triggers several signaling
cascades, such as the mitogen-activated protein kinase (MAPK)
and AKT pathways, which result in proliferation, invasion, and/or
prevention of apoptosis. Overexpression of Met and/or HGF/SF
correlates with aggressiveness and poor outcome in most human
cancers (www.vai.org/met) [4]. Since Met-HGF/SF signaling is
involved in the progression of so many human cancers, it has the
potential for being a significant therapeutic target. Currently, there
are at least 12 Met and HGF/SF inhibitors in clinical trials [8];
these range from small molecule inhibitors to monoclonal
antibodies tested against a wide spectrum of cancers.
Mutational activation of Met can induce tumor growth. Kinase
domain mutations in Met are found in papillary renal carcinomas
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13586[9,10]. This was the first observation to indicate that Met plays a
role in tumor initiation in human cancer. More recently, Met
mutations have been identified within the sema domain,
juxtamembrane domain, and intronic regions in small cell and
non-small cell lung cancers, lung adenocarcinomas, gastric cancer,
renal carcinomas, and mesotheliomas [11,12,13,14,15]. Thus,
mutational activation of Met is not restricted to renal cancers and
may be a more common mechanism by which Met is aberrantly
activated during tumorigenesis. Further studies have shown that
several of these mutations induce resistance to several Met kinase
inhibitors [16,17,18]. Therefore, additional studies are required to
understand the effect of Met mutations in tumor progression and
therapeutic resistance.
Mouse models have been essential for understanding the roles of
tyrosine kinases in both normal mammalian development and
tumorigenesis. To understand the role of Met in tumor
development and progression, we have utilized a unique mouse
model that allows us to compare four different mutations knocked
into the Met genomic locus [19]. These Met mutants range from
high to low in tyrosine kinase activity [20,21,22] and develop a
unique tumor spectrum of primarily sarcomas and lymphomas on
a C57BL/6;129/SV (B6) background [19]. Based on similar
observations in other model systems showing that genetic
background could have a profound influence on the tumor
spectrum [23], we assessed the effect of these Met mutations in
another genetic background.
We first evaluated the effect of the activating Met mutation
M1248T/L1193V on the FVB/N (FVB) background [24].
M1248T and L1193V were first identified as somatic mutations
in renal carcinomas and when combined as M1248T/L1193V
have the highest kinase activity [9,20,22]. FVB mice carrying this
mutation develop aggressive mammary carcinomas with varied
histological features similar to basal-like breast cancers. This
phenotype provided us with a unique opportunity to evaluate the
role of Met in breast cancer. Further evaluation of human breast
cancer tissues determined that MET overexpression was highly
correlated with ER
–/ERBB2
– and basal-like breast cancers [24].
To gain insight into how specific Met mutations induce
tumorigenesis, we utilized the panel of knock-in mutations we
previously generated. For this purpose we created congenic lines of
the Met tyrosine kinase domain mutations M1248T, Y1228C, and
D1226N, on the FVB background. Interestingly, except for
D1226N, each mutation was associated with a distinct tumor
spectrum compared to the identical mutation on the B6
background. Since the only differences between these animals
are the Met mutations and the background, this study illustrates
that either the kinase mutational structure itself or the level of
kinase they impose (or both) influence the tissue-specificity for
tumor formation. However, it also clearly demonstrates that
mutation-specific tumor spectra are dramatically affected by the
mouse background and sets the stage for future work aimed at
defining which modifier loci genetically interact with Met
mutations to influence the tumor spectrum.
Results
Assessing mutational activation of Met on the FVB
background
Previously, we developed a knock-in mouse model of activating
mutations in the Met receptor [19]. This model contains germline
mutations in the endogenous met locus. For these studies,
heterozygous animals were used due to the embryonic lethality
that was observed in homozygous Met
M1248T, Met
Y1228C, and
Met
M1248T/L1193V mice. Some homozygous knock-in animals were
also aged for the Met
D1226N line. Each line carried one mutant
allele expressed under the endogenous promoter; therefore
phenotypic differences were not due to differences in insertion
sites (as found in transgenic models).
Four mouse lines were initially generated on a B6 background
and are referred to according to the effect the change has on the
amino acid sequence of Met: B6-Met
D1226N; B6-Met
Y1228C; B6-
Met
M1248T; and B6-Met
M1248T/L1193V. Previously, we found with
the FVB strain that the FVB-Met
M1248T/L1193V line was more
permissive for tumor formation and on this background a
dramatic shift in tumor type occurred from rare and infrequent
carcinomas to highly aggressive mammary carcinomas [24]. As
previously described [24], both nulliparous and multiparous FVB-
Met
M1248T/L1193V females developed aggressive mammary carci-
nomas on average by 11 months. Although other tumor types were
identified, mammary carcinomas were the predominant tumor
and present in 70% of female FVB-Met
M1248T/L1193V mice.
Expecting to see similar changes in tumor frequency and type,
we created congenic strains on the FVB background for the other
three Met alleles (D1226N; Y1228C; and M1248T). Nulliparous
and multiparous females heterozygous for each knock-in mutation
were aged until tumor growth required euthanasia. Morbidity was
observed in several animals unrelated to tumor growth as detailed
below.
The FVB-Met
M1248T/L1193V line developed tumors more rapidly
than the three other mutant lines (Figure 1 and Table 1). The
average survival age in the FVB-Met
M1248T/L1193V mice was 11.0
months; the average age in the other three lines ranged from 12.6
to 18.3 months (differences with FVB-Met
Y1228C (p=0.005) and
FVB-Met
M1248T (p,3610
26) were statistically significant). Parity
decreased the time of tumor onset in the FVB-Met
M1248T/L1193V
mice but had a less predictable effect in the other lines (Figure 1).
Multiparous females in the FVB-Met
M1248T line had a shorter
survival (15.8 months) than the FVB-Met
M1248T nulliparous females
(21.8 months), yet in the FVB-Met
Y1228C and FVB-Met
D1226N lines,
multiparous females survived slightly longer than the nulliparous
females. The differences between the lines are likely due to the
predominant tumor phenotypes described below.
Mutation-specific profiles are generated on the FVB
background
The tumor profiles among the four mutant FVB lines were
strikingly different (Table 2). Carcinomas were prevalent in FVB-
Met
M1248T/L1193V mice; however, B6-Met
M1248T/L1193V mice did
not develop epithelia neoplasias in any tissue aside from a single
occurrence of lung adenoma. Mammary tumors were the
predominant cause of death in FVB-Met
M1248T/L1193V mice;
however, several animals also developed sarcomas or lymphomas.
Once mammary tumors were identified, subsequent tumor growth
was rapid in the FVB-Met
M1248T/L1193V mice, especially in the
multiparous females. This rapid growth likely resulted in the
survival differences observed between the FVB-Met
M1248T/L1193V
mice and the other mutant lines (Figure 1). Only 18% of the FVB-
Met
M1248T mice developed mammary adenocarcinomas, whereas
four animals developed bronchial alveolar adenocarcinomas and
lymphomas, including histiocytic sarcomas (Table 2 and
Figure 2A–B). Uterine leiomyoma and endometrial hyperplasia
were rare observations. In the FVB-Met
M1248T mice, sarcomas
were also rare (1 out of 22 animals), which is consistent with the
lack of sarcomas observed in B6-Met
M1248T mice [19]. In the FVB-
Met
Y1228C mice, 24% developed mammary adenocarcinomas, but
only one sarcoma and two lymphomas were observed (Table 2 and
Figure 2C–D). The FVB-Met
Y1228C line is the only other line to
develop endometrial hyperplasia similar to that in the FVB-
Met Induces Unique Tumors
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M1248T mice. However, this was only observed in one animal,
and larger numbers of mice are necessary to determine if this is a
significant phenotype. In the Met
D1226N line, hemangiosarcomas
were the predominant phenotype and were observed in 33% of
FVB-Met
D1226N (mu/+ and mu/mu) mice and in 72% of B6-
Met
D1226N (mu/mu) mice [19]. This is the only tumor type for any
of the four knock-in mutations that was consistently observed on
both backgrounds. Surprisingly, the majority of the hemangiosar-
comas in the Met
D1226N mice were identified in the mammary pad
(Table 2 and Figure 2E–F); this is an uncommon location for
hemangiosarcomas in mice. Only one mammary adenocarcinoma
was observed in this line. In each of the lines, bronchial alveolar
adenocarcinomas were identified. However, it is not clear whether
this is specifically associated with the Met mutations as this is a
relatively common neoplasm observed in wild-type FVB animals
(observed in 18% of FVB/N females by 24 months) [25].
Several mice in each line were euthanized due to signs of
morbidity that were not associated with any signs of tumor
development; these included several animals that displayed
enlarged abdomens with increased abdominal fat. Several animals
were also euthanized due to hypoactivity and pathologic
evaluation did not reveal cause of morbidity. A few mice had
cellular infiltrates in multiple organs consistent with bacterial
infection. These animals are designated as ‘‘Nonremarkable’’ in
Table 2.
Distinct mammary phenotypes are observed in Met
mutant lines
Because we observed distinct tumor profiles among the Met
mutant lines on the B6 background, the mutation-specific
differences we observed on the FVB background were not
unexpected. The occurrence of diverse tumor patterns on two
backgrounds confirmed that the germline Met mutations induce
tumorigenesis in multiple cell types. However, there appeared to be
mutation-specific variation among the mammary tumor histopa-
thology. As previously mentioned, the FVB-Met
M1248T/L1193V mice
hadthemostpenetrantmammarytumorigenicphenotype(Table2).
In addition, the mammary tumors that developed in FVB-
Met
M1248T/L1193V females had a wide range of pathological diversity
[24], including squamous metaplasia, solid and tubular patterns,
and myoepitheliomas (Figure 3A–B). In contrast, FVB-Met
M1248T
mammary tumors displayed only tubular and acinar patterns
without any observed squamous metaplasia (Figure 3C–D). The
histological appearance of FVB-Met
Y1228C mammary tumors was
more consistent with that of the FVB-Met
M1248T/L1193V phenotype,
where 60% of FVB-Met
Y1228C mammary tumors contained
significant squamous metaplasia and 40% displayed solid and
tubular patterns (Figure 3E–F). We also observed mammary
hyperplasiain2of21FVB-Met
Y1228Cmice.Increased Metactivation
and expression was present in each of the FVB-Met
M1248T/L1193V
mammary tumor types (Figure 4). All tumors found in the FVB-
Met
M1248T, FVB-Met
Y1228C, and FVB-Met
D1226N mice were unifocal
(62 total animals) whereas multifocal tumors were identified in 6
FVB-Met
M1248T/L1193V females (of 56 total) characterized. Although
multifocal mammary tumors are not unique in mouse models, the
fact that the multifocal FVB-Met
M1248T/L1193V tumors had distinct
morphologic patterns is uncommon. The most remarkable case was
a FVB-Met
M1248T/L1193V mouse that developed two contiguous
tumors with distinctive morphologic characteristics in the
Figure 1. Survival analysis of Met mutant mice. Kaplan-Meier
survival curves of A) all female animals, B) multiparous (.1 litter)
females, and C) nulliparous females.
doi:10.1371/journal.pone.0013586.g001
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opposed borders consistent with expansile growth of both tumors.
These contiguous tumors included an adenocarcinoma with
squamous metaplasia and fibromatous changes (Figure 5B) and an
adenocarcinoma with solid patterns (Figure 5C). These distinctive
tumors, along with the other FVB-Met
M1248T/L1193V mice that
developed multiple distinctive mammary tumors, suggests that
mutationally activated Met is being expressed in a progenitor
population leading to diverse mammary pathology.
Discussion
Previously we have shown that activating knock-in mutations in
the Met kinase domain unexpectedly gave rise to mutation-specific
tumor profiles on the B6 background. For example, B6-Met
M1248T
mice develop carcinomas, whereas B6-Met
D1226N mice primary
developed hemangiosarcomas. Here we asked two questions: when
expressed on a different background (FVB), will activating Met
mutations induce the same tumor type specificity? And what role,
if any, does the host background play?
When knock-in activating alleles were placed on the FVB
background, tumor latency significantly decreased and a more
highly penetrant carcinoma phenotype was generated. Since this is
a knock-in mouse model, each mutation is expressed under the
endogenous promoter, and therefore phenotypic differences were
not due to differences in insertion sites or differential expression
levels. The variation in tumor profiles observed on both the B6
and FVB backgrounds is markedly comparable to the diverse
allele-specific spectra observed in p53-deficient mouse models of
Li-Fraumeni syndrome [26]. The striking phenotypic differences
observed for each mutation may be due to differential genetic
interactions with modifying alleles or cell-type dependent signaling
interactions (i.e. endothelial vs. epithelial).
Several of the tumor-specific phenotypes were consistent
between the B6 and FVB backgrounds. For instance, the
Met
D1226N mice developed hemangiosarcomas at a high frequency
Table 1. Aging data for nulliparous and multiparous females for FVB-Met mutant lines.
M1248T/L1193V M1248T Y1228C D1226N
Total 56* 22 21 19
Nulliparous 28 9 9 12
Multiparous 27 13 12 7
Avg Age (months) 11.0 18.3 16.3 12.6
Multiparous Average Age (months) 9.3 15.8 18.9 12.8
Nulliparous Average Age (months) 12.8 21.8 14.3 11.9
Average age represents average time to death in months. *The parity of one FVB-Met
M1248T/L1193V female was not recorded and this mouse was only included in the
overall age statistics.
doi:10.1371/journal.pone.0013586.t001
Table 2. Histopathology of Met mutant lines on the FVB and B6 backgrounds.
M1248T/L1193V M1248T Y1228C D1226N
FVB B6 FVB B6 FVB B6 FVB B6
Carcinomas
Mammary adenocarcinoma 39 – 4 – 5 – 1 –
Salivary gland squamous carcinoma – – – – – – 1 –
Brochial alveolar adenocarcinoma 1 – 3 1 2 – 1 –
Transitional cell carcinoma – – – 1 – – – –
Squamous cell carcinoma – – – 1 – – – –
Hemangiosarcoma 5 4 1 – – 10 5 13
Sarcomas** 3 3 – – 1 2 1 2
Lymphomas* 1 2 2 7 2 6 – –
Uterine leiomyoma – – 1 – – – – –
Endometrial hyperplasia – – 1 – 1 – – –
Nonremarkable
# 93916–9–
Total Mice 56 18 22 17 21 19 19 18
Mammary adenocarcinomas were found with a significantly higher proportion in FVB-Met
M1248T/L1193V compared to B6-Met
M1248T/L1193V mice (p=2.4610
26).
Hemangiosarcomas developed at a higher incidence in B6-Met
Y1228C and B6-Met
D1226N mice compared to the FVB lines (Y1228C, p=.0005; D1226N, p=.01). *Lymphomas
included plasmacytomas and histiocytic sarcomas on the FVB background and lymphoblastic, lymphocytic, histiocytic sarcomas, and follicular center lymphomas on the
B6 background. **Sarcomas included a rhabdomyosarcoma and undifferentiated sarcomas on the FVB background and fibrosarcomas, myxomas, leiomyosarcomas, and
spindle-like sarcomas on the B6 background.
#Animals without any identifiable tumor burden or cause of death are referred to as ‘‘nonremarkable’’.
doi:10.1371/journal.pone.0013586.t002
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M1248T mice rarely
developed sarcomas on either. On the other hand, we also
observed distinct tumor-specific phenotypes between the two
backgrounds. Mammary adenocarcinomas were the most com-
mon neoplasia in all FVB lines, whereas mammary tumors were
not observed on the B6 background. This may be in part due to
the development of parity-associated hyperplasia in FVB females
[27], though mammary adenocarcinomas were also observed in
virgin animals. Mammary adenocarcinomas were most frequent
and had the shortest time of onset in the FVB-Met
M1248T/L1193V
line, which is not unexpected considering that the
Met
M1248T/L1193V double mutant is more tumorigenic in in vitro
and in vivo assays [20].
MET overexpression is observed in 20–30% of human breast
cancers and is a strong, independent predictor of decreased
survival [28,29,30]. In the current study, we identified allele-
specific pathological phenotypes of several Met mutations. FVB-
Met
M1248T/L1193V and FVB-Met
Y1228C mice developed similar
mammary tumors with diverse features such as squamous
metaplasia and solid and tubular patterns. On the other hand,
FVB-Met
M1248T mammary tumors only displayed acinar and
tubular features, but squamous metaplasia was not observed.
These results indicate that activation of Met is able to initiate
neoplasia in multiple mammary cell types and that Met mutations
may uniquely influence cellular differentiation in the mammary
gland during tumorigenic growth.
Figure 2. Spectrum of tumors observed in Met mutants. A) A bronchial alveolar adenocarcinoma and B) a histiocytic sarcoma in a FVB-
Met
M1248T mouse. C) A plasmacytoma and D) a sarcoma in a FVB-Met
Y1228C mouse. E and F) Hemangiosarcomas observed in the mammary pads of two
individual FVB-Met
D1226N mice. All H&E images were taken at 2006magnification.
doi:10.1371/journal.pone.0013586.g002
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(expressed under the endogenous promoter) is able to initiate such
diverse tumor phenotypes. This underscores the affect that even a
modest increase in Met activity may have on cell transformation.
Amplification of the MET allele has been observed in gastric and
lung cancers [15,31,32]. On the other hand, trisomy of
chromosome 7 (containing the MET locus) is sufficient for
papillary renal carcinomas [33]. These observations in human
tumors, in addition to our work in mouse models, suggest that
even minor amplification of the MET allele may have significant
consequences in various cell types. Therefore, future cytogenetic
analysis should evaluate cancers for both high and low levels of
MET amplification.
We show that Met is able to initiate tumorigenesis in multiple cell
types—including epithelial, hematopoietic, and endothelial—on two
distinct mouse backgrounds. The mutation-specific spectra observed
on the FVB strain validate our unique mutation-specific findings on
the B6 background. These results indicate that each mutation has
distincteffectsondownstreamsignalingthatmaybeinfluencedbythe
cellular environment and/or modifying genes. Furthermore, these
results support the numerous studies in human cell lines and tissues
that demonstrate aberrant MET activity is involved in the initiation,
progression, and metastasis of diverse cancers (www.vai.org/
metandcancer). More recently, MET amplification and activation
via HGF/SF has also been implicated in resistance to EGFR
inhibition in lung cancer [31,34]. The fact that Met influences
Figure 3. Mammary tumor histology observed in Met mutants. A) Adenocarcinoma with solid patterns and squamous metaplasia in a FVB-
Met
M1248T/L1193V mouse; B) myoepithelioma in a FVB-Met
M1248T/L1193V mouse; C and D) adenocarcinomas with tubular patterns from two individual FVB-
Met
M1248T mice; E) squamous cell carcinoma observed in a FVB-Met
Y1228C mouse; and F) an adenosquamous carcinoma observed in a FVB-Met
Y1228C
mouse. All H&E images were taken at 2006magnification.
doi:10.1371/journal.pone.0013586.g003
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makes the Met-HGF/SF pathway a critical therapeutic target.
Here we describe a preclinical model in which Met and/or
HGF/SF inhibition can be assessed in multiple tumor types.
Further studies are required to determine which genetic modifiers
influence the tumorigenic phenotype of an activating Met
mutation. Met mutations have been identified in a wide range of
tumors including renal carcinomas, mesotheliomas, gastric
carcinomas, and non-small cell and small cell lung cancers.
Therefore, it is imperative that we advance our understanding of
which factors genetically influence or interact with Met. Greater
insight into the interaction of genetic modifiers of Met signaling
will significantly impact on our ability to tailor combination
therapies for Met-driven cancers.
Materials and Methods
Animals
Germline knock-in lines were derived on a mixed C57BL/6
background as previously described [19]. Congenic FVB/N
animals were derived by speed congenic MAX-BAX
SM back-
crossing (Charles River Laboratories). Animals were housed in the
VAI Vivarium. Housing and care of the animals were in strict
accordance with the guidelines established by the VAI Institutional
Animal Care and Use Committee. All research involving animals
was approved by the VAI Institutional Animal Care and Use
Committee (Permit Numbers: 05-08-023 and 08-10-029).
Tumor analysis
Mice were examined biweekly for tumor development and were
euthanized when tumors were between 1–2 cm
3. Tumor samples
along with selected organs were surgically isolated and fixed in 4%
paraformaldehyde/phosphate-buffered saline for 24 h. Fixed
tissues were dehydrated, paraffin-embedded, cut into 5-mm
sections, and stained with hematoxylin and eosin (H&E).
Immunoprecipitation and Western Blot Analyses
Tissue was homogenized in SBN lysis buffer [50 mM Tris
(pH 7.5), 150 mM NaCl, 10% glycerol, 1% Nonidet P-40, 1 mM
Figure 4. Met activation and expression is increased in FVB-
Met
M1248T/L1193V mammary tumors. Western blot analysis of immu-
noprecipiated lysates showed increased Met activation (phospho-Met)
and expression in mammary tumors isolated from FVB-Met
M1248T/L1193V
mice compared to normal FVB-Met
M1248T/L1193V mammary pads. Met
activation and expression was increased in all of the pathologic types
observed in the FVB-Met
M1248T/L1193V mammary tumors.
doi:10.1371/journal.pone.0013586.g004
Figure 5. Contiguous tumors observed in a Met
M1248T/L1193V
mouse. A) Two adjacent mammary tumors within a FVB-Met
M1248T/L1193V
mouse (406 magnification). B) Adenocarcinoma shown in A with
squamous metaplasia and fibromatous changes (2006magnification). C)
Adenocarcinoma shown in A with solid patterns (2006magnification).
doi:10.1371/journal.pone.0013586.g005
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Inhibitor Mixture Tablets (Roche Applied Science). For immu-
noprecipitation, 0.5 mg of protein was incubated overnight with
anti-Met antibody (B-2, Santa Cruz Biotechnology) at 4uC.
Immune complexes were collected with protein A-Sepharose
beads (RepliGen) and washed three times in HNTG buffer
[20 mM HEPES (pH 7.5), 150 mL NaCl, 0.1% TritonX-100,
10% glycerol]. Immunoprecipitated lysates were separated on a 4–
20% Tris-glycine gel (Invitrogen), transferred to a nitrocellulose
membrane (Invitrogen), and examined by Western analysis using a
phospho-Met (Tyr1234/1235) antibody (Clone 3D7, Cell Signal-
ing) and an anti-Met antibody (B-2).
Statistical Analysis
Survival was determined using the Kaplan and Meier survival
function. Pairwise comparisons of survival curves were done using
a log-rank test. To compare differences in the proportion of tumor
types in each background, a two proportion z test for equal
proportions was used. Proportions were considered significantly
different if the p-value ,0.05.
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